Lunai Bioworks and BrainStorm Therapeutics have signed a Master Collaboration Agreement to combine AI and human brain organoid technology for Parkinson's disease research. Their integrated approach aims to identify patient subtypes, biomarkers, and therapeutic targets, with initial data expected in early 2027. This collaboration could improve clinical trial design, biomarker development, and create partner-ready drug programs, addressing Parkinson's disease heterogeneity with precision medicine.
Crypto analyst Dark Defender suggests XRP's price pattern resembles those before its major rallies in 2014 and 2017, indicating it might be ready for a significant move soon. This setup appears independent of the upcoming Sept. 15 Senate vote on the ...
Bleichmar Fonti & Auld LLP is investigating Coastal Financial Corporation for potential securities fraud related to its banking as a service segment and CCBX partner relationships. The probe follows a sharp 43.5% stock drop on July 30, 2026, after Co...
BFA Law is investigating Cardinal Infrastructure Group, Inc. for potential securities fraud related to misleading statements about the performance of its acquisition, A.L. Grading Contractors. On August 11, 2026, Cardinal's stock dropped over 36% aft...
Gamehaus Holdings Inc. announced a 20.8% revenue decline to $24.3 million in Q4 2026, driven by reduced user acquisition spending and marketing adjustments. Despite lower revenue, net income fell 38.2% to $0.9 million, while operating costs decreased...
Waterdrop Inc. posted strong Q2 2026 results with net operating revenue up 72.8% year-over-year to RMB1.45 billion (US$213.4 million), driven by an 80.5% increase in insurance-related income. Operating profit rose 14.3% year-over-year to RMB111.3 mil...
